Retrospective Analyses Versus RCTs: Comparing Like with Like?

Overview

Journal J Pain Res

Publisher Dove Medical Press

Date 2017 Apr 25

PMID 28435315

Citations 3

Authors

Ralf Baron

Lieven Nils Kennes

Christian Elling

Affiliations

Soon will be listed here.

Citing Articles

Tapentadol: an overview of the safety profile.

Polati E, Canonico P, Schweiger V, Collino M J Pain Res. 2019; 12:1569-1576.

PMID: 31190968 PMC: 6529613. DOI: 10.2147/JPR.S190154.

Tapentadol for neuropathic pain: a review of clinical studies.

Freo U, Romualdi P, Kress H J Pain Res. 2019; 12:1537-1551.

PMID: 31190965 PMC: 6529607. DOI: 10.2147/JPR.S190162.

Tapentadol: an effective option for the treatment of back pain.

Coluzzi F, Polati E, Freo U, Grilli M J Pain Res. 2019; 12:1521-1528.

PMID: 31190963 PMC: 6526923. DOI: 10.2147/JPR.S190176.

References

Hansson L, Hedner T, Dahlof B . Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Press. 1992; 1(2):113-9. DOI: 10.3109/08037059209077502. View

Baron R, Likar R, Martin-Mola E, Blanco F, Kennes L, Muller M . Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study. Pain Pract. 2015; 16(5):580-99. DOI: 10.1111/papr.12308. View

Ueberall M, Mueller-Schwefe G . Efficacy and tolerability balance of oxycodone/naloxone and tapentadol in chronic low back pain with a neuropathic component: a blinded end point analysis of randomly selected routine data from 12-week prospective open-label observations. J Pain Res. 2016; 9:1001-1020. PMC: 5115682. DOI: 10.2147/JPR.S112418. View